Skip to main content

Table 3 SARS-CoV-2 antibody prevalence by population

From: Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland

 

Nursing home & home healthcare populations

Population sample

Total N

No presence of antibodies

Presence of antibodies

Total N

No presence of antibodies

Presence of antibodies

Total participants

427

378

49 (11.5%)

472

453

19 (3.5%a)

Asymptomatic (since January 2020)

49

40

9 (18.4%)

18

14

4 (22.2%)

Age mean (sd)

43.8 (13.2)

43.7 (13.1)

45.4 (13.9)

44.7 (11.7)

44.6 (11.7)

46.2 (11.0)

Sex

      

 Female

361

319

42 (11.6%)

246

239

7 (2.8%)

 Male

65

59

6 (9.2%)

226

214

12 (5.3%)

Smoking status

      

 Current smoker

114

108

6 (5.3%)

102

95

7 (6.9%)

 Ex-smoker

79

69

10 (12.7%)

117

112

5 (4.3%)

 Never smoker

208

179

29 (13.9%)

252

245

7 (2.8%)

Citizenship

      

 Swiss

313

276

37 (11.8%)

358

342

16 (4.5%)

 Other

115

101

12 (10.6%)

114

111

3 (2.6%)

Education

      

 Primary

49

40

9 (18.4%)

13

12

1 (7.7%)

 Secondary

206

184

22 (10.7%)

185

179

6 (3.2%)

 Tertiary

140

128

12 (8.6%)

268

256

12 (4.5%)

Number of other people in the same household

      

 0

64

58

6 (9.4%)

70

68

2 (2.9%)

 1

125

116

9 (7.2%)

176

167

9 (5.1%)

 2 or more

206

180

26 (12.6%)

222

214

8 (3.6%)

Chronic conditions

      

 No chronic condition

321

286

35 (10.1%)

378

364

14 (3.7%)

 1 or more chronic conditionsb

79

70

9 (11.4%)

93

88

5 (5.4%)

BMI (mean, sd)

25.4 (4.8)

25.3 (4.8)

26.0 (5.0)

24.9 (4.9)

25.0 (4.9)

23.1 (3.8)

EQ—5D-5L dimensions

      

 Mobility problems present

52

45

7 (13.5%)

45

42

3 (6.7%)

 Problems with self-care present

33

27

6 (18.2%)

5

5

0 (0.0%)

 Problems during usual activities present

42

36

6 (14.3%)

36

35

1 (2.9%)

 Pain or discomfort present

157

141

16 (10.2%)

134

128

6 (4.5%)

 Anxiety or depression present

106

98

8 (7.6%)

117

109

8 (6.8%)

EQ visual analogue scale (0 = worst; 100 = best) mean (sd)

86.0 (12.3)

85.9 (12.4)

86.4 (11.4)

85.3 (11.6)

85.2 (11.6)

86.3 (11.8)

Episodes of symptoms in 2020, at least for 3 days

      

 No

194

179

15 (7.7%)

190

185

5 (2.6%)

 1 or more

233

199

34 (14.6%)

282

268

14 (5.2%)

Previous SARS-CoV-2 test results

      

 Tested positive for SARS-CoV-2

18

3

15 (83.3%)

0

0

0 (0.0%)

 Tested negative for SARS-CoV-2

163

150

13 (8.0%)

40

38

2 (5.0%)

 No test done

208

194

14 (6.7%)

429

412

17 (4.0%)

Number of people in immediate environment previously tested positive for SARS-CoV-2

    

 0

339

308

31 (9.1%)

424

407

17 (4.0%)

 1

18

15

3 (16.7%)

17

16

1 (5.9%)

 2 or more

68

54

14 (20.6%)

31

30

1 (3.2%)

Adherence to preventative measures in the last 7 days (1 = never; 5 = always), mean (sd)

 Keeping social distance

4.1 (0.9)

4.1 (0.9)

4.2 (0.9)

4.1 (0.7)

4.1 (0.8)

4.2 (0.5)

 Only leaving house for essential tasks

3.4 (1.1)

3.4 (1.1)

3.6 (0.9)

3.2 (1.1)

3.2 (1.1)

3.3 (1.1)

 Wearing face mask

4.4 (0.8)

4.4 (0.8)

4.4 (0.7)

3.0 (1.2)

3.0 (1.2)

2.9 (1.1)

 Adherence to hygiene measures (washing hands, etc.)

4.7 (0.5)

4.7 (0.5)

4.6 (0.7)

4.6 (0.6)

4.6 (0.6)

4.6 (0.6)

Use of SwissCovid App

      

 Yes, regularly

133

123

10 (7.5%)

231

220

11 (4.8%)

 No

266

231

35 (13.2%)

147

140

7 (4.8%)

Number of trips taken outside the country since January 2020

 0

178

158

20 (11.2%)

251

242

9 (3.6%)

 1

110

100

10 (9.1%)

110

107

3 (2.7%)

 2 or more

136

118

18 (13.2%)

111

104

7 (6.3%)

  1. All values are shown as n or n (%) unless otherwise noted
  2. sd standard deviation; BMI Body Mass Index; COVID-19 Coronavirus Disease 2019; DFU Digital Follow Up; PCR Reverse Transcription Polymerase Chain Reaction Test; SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 Infection
  3. aPrevalence estimates for population sample were calculated using a Bayesian logistic regression model and weighted for age, sex and sensitivity/specificity of the antibody test
  4. bExcluding allergies